Merck + Co., Inc.

Merck Sharp + Dohme Corp.

William K Hagmann

Shrenik K Shah

Philippe L Durette

Malcolm MacCoss

Linus S Lin

Paul E Finke

Richard A Mumford

James B Doherty

Soumya P Sahoo

Linda L Chang

Thomas J Lanza, Jr

Ihor E Kopka

Sander G Mills

Charles G Caldwell

Richard L Tolman

Mitree M Ponpipom

Gary H Rasmusson

Ping Liu

Ravindra N Guthikonda

James Patrick Jewell

Stephen E DeLaszlo

Ravi P Nargund

George A Doherty

Hubert B Josien

Bin Hu

Conrad P Dorn

Malcolm Maccoss

Purakkattle J Biju

Theodore M Kamenecka

Derek J Von Langen

Hongbo Qi

Donald W Graham

Kevin Tyler Chapman

Bing Li

Christopher W Plummer

Zhengxia Chen

Timothy Allen Blizzard

Tesfaye Biftu

Qun Dang

Mark T Goulet

Barbara A Pio

Jeffrey John Hale

Raymond A Firestone

Haifeng Tang

Fa-Xiang Ding

Guoqing Li

Cheng Zhu

Jing Su

Li Xiao

Harry R Chobanian

Shuzhi Dong

Haiqun Tang

Quang T Truong

Weidong Pan

Anilkumar G Nair

George A Doss

Dexi Yang

Stephen E De Laszlo

Mihir Mandal

Shu-Wei Yang

William F Hoffman

Alexander Pasternak

Nicholas D Smith

Bruce E Witzel

Michael W Miller

Dong Xiao

Steven L Colletti

Jinlong Jiang

Nicholas Simon Stock

Jian Liu

Shuwen He

Liangqin Guo

Duane E DeMong

Alan L Maycock

Bowei Wang

Derun Li

Helen Y Chen

Xin Gu

Thomas S Reger

Yan Guo

Linda Brockunier

Clare London

Timothy A Blizzard

Zhiqiang Zhao

Jacqueline D Hicks

Jianping Pan

Jessica Frie

Yuhua Huang

Susan D Aster

Meibi Dai

Katherine Young

Zhong Lai

Alejandro Crespo

Nam Fung Kar

Joung L Goulet

Jason W Szewczyk

Nathan G Steinberg

Terence G Hamill

H Donald Burns

Raymond E Gibson

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

Antidiabetic bicyclic compounds

The present invention relates to compounds of formula I that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

The present invention relates to compounds of formula (I) that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Metallo-beta-lactamase inhibitors

Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. 

Oxadiazole beta carboline derivatives as antidiabetic compounds

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted amides

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

Radiolabeled cannabinoid-1 receptor modulators

Bicyclic amides

Substituted pyridyoxy amides

Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.

VLA-4 antagonists

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists

Growing community of inventors

Westfield, NJ, United States of America

William K Hagmann